Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ESPR, NIKA, BIOA: Debt-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Debt-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Debt-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a Debt-to-Asset of 0.40 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Amphastar Pharmaceuticals and its competitors.
Is Amphastar Pharmaceuticals' Debt-to-Asset too high?
Amphastar Pharmaceuticals' current Debt-to-Asset is 0.40. Overall, Amphastar Pharmaceuticals has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Debt-to-Asset compare to ESPR and NIKA?
Amphastar Pharmaceuticals' Debt-to-Asset of 0.40 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Debt-to-Asset is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.67, compared to a current price of $20.94 — trading 41.3% below its estimated fair value. The current Debt-to-Asset is 0.40. Amphastar Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Debt-to-Asset is 0.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.94 is trading 41.3% below its estimated GF Value™ of $35.67.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Debt-to-Asset: 0.40
GF Value™: $35.67 vs. price of $20.94 (41.3% below fair value)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
77GF Score
Get the complete analysis for AMPH
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
